Skip to content

Study · Not a test of the peptide alone · 2007

1 result

Lean rats with hypothalamic pro-opiomelanocortin overexpression exhibit greater diet-induced obesity and impaired central melanocortin responsiveness.

Li G, Zhang Y, Cheng KY, Scarpace PJ

Diabetologia16 May 2007Cited by 11 (Europe PMC)

PMID17505816 (opens in a new tab)DOI10.1007/s00125-007-0685-1 (opens in a new tab)PepBankPUB-17505816
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In lean rats, hypothalamic Pomc gene delivery impaired the anorexic response to melanotan II.

    In plain wordsIn rats, extra Pomc gene delivery weakened the appetite-reducing response to melanotan II.

    Peptide
    Melanotan II
    Outcome
    DecreaseAnorexic response to MTII after rAAV-Pomc
    Study

    ratn: not reported in source

    lean rats given rAAV-Pomc
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    The anorexic response to MTII was impaired
    1 context sentence
    Summary · context
    We examined energy balance and responsiveness to the melanocortin agonist melanotan II (MTII) or the antagonist SHU9119.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.